Novavax Inc said recently its COVID-19 vaccine has got Emergency Use Authorisation (EUA) from the Drugs Controller General of India (DCGI) for children aged 12 to 17 years.
The authorisation is a global first for the age group for the vaccine, which is manufactured and marketed by the Serum Institute of India (SII) under the brand name Covovax.
Novavax last month said its vaccine was 80 per cent effective against COVID-19 in a late-stage trial testing the shot in 2,247 teens aged 12 to 17 years.
The company said its vaccine produced an immune response in the same age group in a mid-to late-stage study involving 460 Indian adolescents.
Covovax is the fourth COVID-19 vaccine to be authorised for adolescents aged 12 years and older in India after Biological E’s Corbevax, Zydus Cadila’s ZyCoV-D and Bharat Biotech’s Covaxin.
Edits by EP News Bureau